定喘汤治疗痰热壅肺型哮喘-慢性阻塞性肺疾病重叠综合征的临床效果

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (1078 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Dingchuan Decoction in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) with syndrome of phlegm heat obstructing lung. Methods A total of 95 ACOS patients with syndrome of phlegm heat obstructing lung admitted to Hubei Provincial Hospital of TCM from January 2018 to September 2020 were selected. According to random number table method, they were divided into control group (47 cases) and study group (48 cases). The control group was treated with routine treatment and Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation, and the study group was treated with Dingchuan Decoction on the basis of control group. Both groups were treated for 3 months. The clinical efficacy, inflammatory factor, lung function, clinical symptom score and incidence of adverse reactions were compared between the two groups. Results After treatment, the total effective rate in the study group was higher than that in the control group (P ＜ 0.05). After treatment, interleukin-6, interleukin-10, and high-sensitivity C-reactive protein in the two groups were lower than those before treatment, and study group was lower than control group (P ＜ 0.05). After treatment, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/FVC in the two groups were higher than those before treatment, and study group was higher than control group (P ＜ 0.05). After treatment, asthma control test scores in the two groups were higher than those before treatment, and the study group was higher than the control group (P ＜ 0.05); chronic obstructive pulmonary disease assessment test scores in the two groups were lower than those before treatment, and the study group was lower than the control group (P ＜ 0.05). After treatment, there was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Dingchuan Decoction has a significant curative effect in the curative of ACOS with syndrome of phlegm heat obstructing lung, which can effectively improve the clinical symptoms, lung function and inflammatory factor levels of patients, with good safety and high clinical application value.

Key words： Dingchuan Decoction Asthma-chronic obstructive pulmonary disease overlap syndrome Curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yue1 ZHENG Lan1 GAO Yue2

Cite this article:

LI Yue1 ZHENG Lan1 GAO Yue2. Clinical effect of Dingchuan Decoction in the treatment of asthma-chronic obstructive pulmonary disease overlap syndrome with syndrome of phlegm heat obstructing lung#br#[J]. 中国医药导报, 2021, 18(33): 139-142,168.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I33/139

[1] Hersh CP，Zacharia S，Prakash Arivu Chelvan R，et al. Immunoglobulin E as a Biomarker for the Overlap of Atopic Asthma and Chronic Obstructive Pulmonary Disease [J]. Chronic Obstr Pulm Dis，2020，7（1）：1-12.
[2] 梁静波，方秋红.支气管哮喘-慢性阻塞性肺疾病重叠综合征的研究进展[J].中国老年学杂志，2017，37（7）：1784-1786.
[3] Ioachimescu OC，Janocko NJ，Ciavatta MM，et al. Obstructive Lung Disease and Obstructive Sleep Apnea（OLDOSA）cohort study：10-year assessment [J]. J Clin Sleep Med，2020，16（2）：267-277.
[4] 洪儿，王海霞，陈希尔，等.止咳平喘十二味合剂联合信必可都保治疗痰热壅肺型哮喘-慢阻肺重叠综合征疗效观察[J].浙江中西医结合杂志，2019，29（9）：729-731.
[5] 杨一民，洪菲萍，曾谷兰，等.加味定喘汤对儿童哮喘临床效果及炎性介质水平的影响[J].中国中西医结合杂志，2020，40（6）：691-695.
[6] Miravitlles M，Soler-Catalu?觡a JJ，Calle M，et al. Spanish COPD Guidelines（GesEPOC）：Pharmacological treatment of stable COPD [J]. Aten Primaria，2012，44（7）：425-437.
[7] 白小林.现代中医内科学[M].长春：吉林科学技术出版社，2012.
[8] Nathan RA，Sorkness CA，Kosinski M，et al. Development of the asthma control test：a survey for assessing asthma control [J]. J Allergy Clin Immunol，2004，113（1）：59-65.
[9] Jones PW，Harding G，Berry P，et al. Development and first validation of the COPD Assessment Test [J]. Eur Respir J，2009，34（3）：648-654.
[10] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[11] 汤洪.哮喘-慢性阻塞性肺疾病重叠综合征临床特征及防治措施探讨[J].数理医药学杂志，2019，32（12）：1760-1761.
[12] Albertson TE，Chenoweth JA，Pearson SJ，et al. The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome（ACOS）[J]. Expert Opin Pharmacother，2020，21（2）：213-231.
[13] 喻勇，宁保明，舒宏，等.哮喘和慢性阻塞性肺疾病用药现状及新药研究进展[J].中国新药杂志，2018，27（2）：159-166.
[14] Moussa Ounteini A，Aziagbe Koffi A，Rabiou S，et al. Un cas clinique de syndrome d’hyperplasie neuroendocrine pulmonaire diffuse idiopathique [A case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia（DIPNECH）syndrome] [J]. Rev Mal Respir，2020，37（1）：75-79.
[15] Kalemci S，Sar?覦han A，Zeybek A. Is Asthma and COPD Overlap Syndrome Weather and Environment Sensitive? [J]. Lung，2020，198（1）：241-242.
[16] 赵小鹏，乔树斌.定喘汤联合布地奈德福莫特罗治疗咳嗽变异性哮喘疗效及对外周血细胞间黏附分子-1、嗜酸细胞活化趋化因子的影响[J].世界中西医结合杂志，2020，15（1）：107-110.
[17] 李峥嵘，季永欣，王乔.固肾定喘汤加减对AECOPD的疗效及SP-D CC-16和肺功能的影响[J].浙江临床医学，2019，21（5）：628-630.
[18] 林国庆.加减定喘汤治疗支气管哮喘急性发作热哮证36例临床效果分析[J].中医临床研究，2017，9（35）：14-15.
[19] 赵宁，谭楠，刘婷婷.布地奈德雾化联合胸腺肽α-1治疗哮喘慢性阻塞性肺疾病重叠综合征临床效果及对患者血清炎症因子影响分析[J].陕西医学杂志，2018， 47（7）：927-930.
[20] 胡海涛，曾丽娟，屈磊，等.噻托溴铵联合吸入糖皮质激素对哮喘-慢性阻塞性肺疾病重叠综合征患者肺功能、FeNO及免疫功能的影响[J].空军医学杂志，2017， 33（2）：113-117.
[21] 左军，牟景光，胡晓阳.半夏化学成分及现代药理作用研究进展[J].辽宁中医药大学学报，2019，21（9）：26-29.
[22] 李思佳，耿剑亮，张悦，等.银杏药理作用研究进展[J].药物评价研究，2017，40（6）：731-741.
[23] 赵玉升，胡杰，吴佳姝，等.苦杏仁炮制方法及药理作用研究进展[J].中医药导报，2021，27（3）：175-180.
[24] 姚雪，吴国真，赵宏伟，等.黄芩中化学成分及药理作用研究进展[J].辽宁中医杂志，2020，47（7）：215-220.
[25] 陈千，熊富良，张雪琼，等.甘草苷对感染后咳嗽（肺阴虚证）小鼠的止咳作用机制及抗氧化作用的研究[J].华中师范大学学报：自然科学版，2020，54（5）：841-848，873.